Voyager Therapeutics Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Boston, MA USA
Total Funding:$205M
Lead Investor(s):Morgan Stanley, Cowen
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Voyager Therapeutics's estimated annual revenue is currently $7.6M per year.
  • Voyager Therapeutics received $75.0M in venture funding in November 2017.
  • Voyager Therapeutics's estimated revenue per employee is $35,770
  • Voyager Therapeutics's total funding is $205M.

Employee Data

  • Voyager Therapeutics has 213 Employees.
  • Voyager Therapeutics grew their employee count by 41% last year.
  • Voyager Therapeutics currently has 1 job openings.

Executive Contacts

Praveen MalhotraDirector, Enterprise Platforms
Robert PietruskoSenior Vice President, Regulatory Affairs & Quality Assurance
Xiaobing LiVice President, Program Management
Patricia PorterClinical Trial Site Manager
Steven HerschVice President, Clinical Research And Development
Kyle GrantAssociate Director
Srinivas ChollangiAssociate Director
Luis MarangaChief Technical Operations Officer
Rajiv GangurdeDirector, Chemistry, Manufacturing & Controls (cmc)
Hatim ZariwalaAssociate Director

Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 857-259-5340



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
Tango Therapeut...
Compass Therape...
Hamilton Storag...
Alnylam Pharmac...
Berkshire Corpo...
Repligen Corpor...
Allena Pharmace...

Voyager Therapeutics News

09/05/2019 - The Majority of Analysts Are Still Bullish on Voyager ...

On Wednesday, shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) marked $16.77 per share versus a previous $17.11 closing price.

55 menit yang lalu - Voyager Therapeutics Inc (NASDAQ:VYGR) Shares Acquired ...

DekaBank Deutsche Girozentrale lifted its stake in Voyager Therapeutics Inc (NASDAQ:VYGR) by 63.6% in the 2nd quarter, according to the ...

09/05/2019 - Morning Stock Gigantic Turns: Voyager Therapeutics, Inc ...

On Thursday's Current Session, Voyager Therapeutics, Inc. (NASDAQ:VYGR) closing at $17.00 price level during recent trade its distance from ...

Voyager Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-02-13$45.0MAThird Rock VenturesArticle
2015-04-14$60.0MBBrookside CapitalArticle
2017-11-08$75.0MUndisclosedMorgan StanleyArticle

Voyager Therapeutics Executive Hires

2014-06-27Robert G. PietruskoSVP Regulatory AffairsArticle
2014-09-04Steven PaulCEOArticle
2015-04-29Jeff GoaterVP Finance/Business DevelopmentArticle
2017-01-04Jane HendersonCFO/SVPArticle
2017-09-19Matthew OttmerCOOArticle
2018-06-29Andre TurennePresident and Chief Executive OfficerArticle
2019-01-23Robert HessleinGeneral CounselArticle

Voyager Therapeutics New Location/Offices

2014-10-22Cambridge, MAArticle